BIOMEDAL

"NANOPHOTONIC BIOSENSORS FOR THE DIAGNOSIS AND CLINICAL MANAGEMENT OF BACTERIAL INFECTIONS AT THE POINT OF CARE (PHITBAC)"

Reference: PLEC2021-007739

Duration: 36 months

#

Infections produced by multidrug-resistant bacteria are foreseen to cause the upcoming worldwide pandemic, already being today a major healthcare emergency with thousands of deaths every year. PHITBAC aims to introduce a new, disruptive, and versatile point-of-care nanobiosensor technology for the whole diagnosis and clinical management of bacterial infectious diseases. The groundbreaking diagnostic device will prove rapid detection of most relevant pathogenic bacteria, including an on-site identification of antibiotic resistance, and a personalized monitoring of antimicrobial therapy effectivity.

The PHITBAC project is carried out through a public-private Spanish partnership that includes two research centers of excellence, the Catalan Institute of Nanoscience and Nanotechnology (ICN2, Barcelona) and the National Biotechnology Center (CNB-CSIC, Madrid), two reference public hospitals in infectious diseases, the University Hospital Vall d'Hebron – VHIR and Hospital del Mar – IMIM in Barcelona, and two fully-established innovation companies, Biomedal S.L. (Sevilla) and Aptus Biotech S.L. (Madrid).

PHITBAC project (PLEC2021-007739) is funded by
MCIN / AEI / 10.13039 / 501100011033 and the **European Union NextGenerationEU / PRTR**

MINISTERIO DE CIENCIA E INNOVACIÓN

Financiado por la Unión Europea NextGenerationEU

Plan de Recuperación, Transformación y Resiliencia

AGENCIA ESTATAL DE INVESTIGACIÓN

C/ Calzada Romana, 40
P.I. Parque Plata,
41900, Camas (Spain)

Av. Américo Vespucio, 5-E, P1, M12
Parque Científico y Tecnológico Cartuja 93
41092, Sevilla (Spain)

+ 34 955 98 32 15
info@biomedal.com
www.biomedal.com